nach oben

Erschienen in:

01.09.2012 | Original Paper

Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

verfasst von: Peter H. Wiernik, Zhuoxin Sun, Holly Gundacker, Gordon Dewald, Marilyn L. Slovak, Elisabeth Paietta, Haesook T. Kim, Frederick R. Appelbaum, Peter A. Cassileth, Martin S. Tallman

Erschienen in: Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or all-trans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

Schoch C, Haferlach T, Hasse D, Fonatsch C, Löffler H, Schlegelberger B, Staib P, Sauerland MC, Heinecke A, Büchner T, Hiddemann W. Patients with de novo acute myeloid 1eukaemia and complex karyotype aberrations have a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112:118–26.PubMedCrossRef

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021–8.PubMedCrossRef

Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–56.PubMedCrossRef

Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–9.PubMed

Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92:994–5.PubMedCrossRef

Agresti A. Exact inference for categorical data: recent advances and continuing controversies. Stat Med. 2002;20:2709–22.CrossRef

Landis RJ, Heyman ER, Koch GG. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Stat Rev. 1978;46:237–54.CrossRef

Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220.

Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. MRC Adult Leukaemia Working Party. Br J Haematol. 1996;94:557–73.PubMed

10.

Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia–prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15:1786–95.PubMed

11.

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood. 2002;100:4298–302.PubMedCrossRef

12.

Okoshi Y, Akiyama H, Kono N, Matsumura T, Mizuchi D, Mori S, Ohashi K, Sakamaki H. Effect of additional chromosomal abnormalities in acute promyelocytic leukemia treated with all-trans retinoic acid: a report of 17 patients. Int J Hematol. 2001;73:496–501.PubMedCrossRef

13.

O’Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, Magenis E, Capdeville R, Drucker BJ. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100:1628–33.PubMedCrossRef

14.

Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res. 2003;9:1333–7.PubMed

15.

Le Beau MM, Bitts S, Davis EM, Kogan SC. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood. 2002;99:2985–91.PubMedCrossRef

16.

Wolman SR, Gundacker H, Appelbaum FR, Slovak ML. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2002;100:29–35.PubMedCrossRef

17.

Xu L, Zhao WL, Xiong SM, Su XY, Zhao M, Wang C, Gao YR, Niu C, Cao Q, Gu BW, Zhu YM, Gu J, Hu J, Yan H, Shen ZX, Chen Z, Chen SJ. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia. 2001;15:1359–68.PubMedCrossRef

18.

Schoch C, Hasse D, Haferlach T, Freund M, Link H, Lengfelder E, Löffler H, Büchner T, Fonatsch C. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol. 1996;94:493–500.PubMedCrossRef

19.

De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Soto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stomatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, Fenaux P. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111:801–6.PubMedCrossRef

20.

Hernández JM, Martin G, Gutiérrez NC, Cerva J, Ferro MT, Calasanz MJ, Martinez-Climent JA, Luño E, Tomo M, Rayón C, Díaz-Mediavilla J, González M, González-San Miguel JD, Pérez-Esquiza K, Rivas C, Esteve J, Alvarez Midel C, Odriozola J, Ribera JM, Sanz MA. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline based protocol. A report of the Spanish group PETHEMA. Haematologica. 2001;86:807–13.PubMed

21.

Pantic M, Novak A, Marisavljevic D, Djordjevic V, Elezovic I, Vidovic A, Colovic M. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol. 2000;17:307–13.PubMedCrossRef

22.

Wan TS, Ma SK, Au WY, Liu HS, Chan JC, Chan LC. Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. Cancer Genet Cytogenet. 2003;140:170–3.PubMedCrossRef

23.

Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol. 1997;96:314–21.PubMedCrossRef

24.

Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy—related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosom Cancer. 2002;33:395–400.PubMedCrossRef

25.

Liang JY, Wu DP, Liu YJ, Ma QF, Gong JX, Zhu MQ, Xue YQ, Chen ZX. The clinical and laboratory features of acute promyelocytic leukemia: an analysis of 513 cases. Zhonghua Nei Ke Za Zhi. 2008;47:389–92.PubMed

26.

Lu J, Jiang H, Jiang Q, Bao L, Lu XJ, Zhang Y, Lin W, Liu YR, Huang XJ, Jiang B. Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all-trans retinoic acid plus anthracyclin based protocol. Zhonghua Yi Xue Za Zhi. 2008;88:2254–7.PubMed

Titel: Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)
verfasst von: Peter H. Wiernik
Zhuoxin Sun
Holly Gundacker
Gordon Dewald
Marilyn L. Slovak
Elisabeth Paietta
Haesook T. Kim
Frederick R. Appelbaum
Peter A. Cassileth
Martin S. Tallman
Publikationsdatum: 01.09.2012
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-012-0251-7

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Evaluation of pirarubicin–cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute

The relationship between Bmi-1 and the epithelial–mesenchymal transition in lung squamous cell carcinoma

Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women

Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer

ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study

Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie